Molecular mechanisms behind the inhibitory effects of ginsenoside Rg3 on hepatic fibrosis: a review

Zhao-Feng Tian1, Rui-Yi Hu1, Zi Wang2

  • 1College of Chinese Medicinal Materials, Jilin Provincial International Joint Research Center for the Development and Utilization of Authentic Medicinal Materials, Jilin Agricultural University, Changchun, 130118, China.

Archives of Toxicology
|December 27, 2024
PubMed

Insights

Ginsenoside Rg3, derived from ginseng, shows promise in treating liver fibrosis by reducing inflammation and oxidative stress. This review explores its molecular mechanisms, including autophagy and apoptosis, for potential therapeutic applications.

Area of Science:

  • Hepatology and Pharmacology
  • Natural Product Chemistry

Background:

  • Hepatitis can lead to liver fibrosis, cirrhosis, and cancer.
  • Liver fibrosis is reversible, necessitating new therapeutic targets.
  • Ginseng's active compound, ginsenoside Rg3, exhibits diverse biological activities.

Purpose of the Study:

  • To review the molecular mechanisms of ginsenoside Rg3's anti-fibrotic effects.
  • To highlight ginsenoside Rg3 as a potential therapeutic agent for liver fibrosis.

Main Methods:

  • Literature review of studies on ginsenoside Rg3 and liver fibrosis.
  • Analysis of molecular pathways involved in ginsenoside Rg3's action.

Main Results:

  • Ginsenoside Rg3 demonstrates anti-inflammatory, antioxidant, and anti-fibrotic properties.
  • It may mitigate liver fibrosis by modulating autophagy, apoptosis, and signaling pathways.
  • Evidence suggests a role in reducing hepatic inflammation and oxidative stress.

Conclusions:

  • Ginsenoside Rg3 holds therapeutic potential for liver fibrosis.
  • Understanding its molecular mechanisms can guide future research and treatment strategies.